AstraZeneca Balance Sheet Health
Financial Health criteria checks 3/6
AstraZeneca has a total shareholder equity of $40.8B and total debt of $30.2B, which brings its debt-to-equity ratio to 74%. Its total assets and total liabilities are $104.9B and $64.1B respectively. AstraZeneca's EBIT is $13.7B making its interest coverage ratio 15.3. It has cash and short-term investments of $4.9B.
Key information
74.0%
Debt to equity ratio
US$30.19b
Debt
| Interest coverage ratio | 15.3x |
| Cash | US$4.93b |
| Equity | US$40.81b |
| Total liabilities | US$64.12b |
| Total assets | US$104.92b |
Recent financial health updates
No updates
Recent updates
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
Nov 13AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)
Nov 07AstraZeneca: Buy This Big Pharma Stock At A Discount Now
Sep 24AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data
Sep 12Financial Position Analysis
Short Term Liabilities: AZN's short term assets ($24.2B) do not cover its short term liabilities ($25.9B).
Long Term Liabilities: AZN's short term assets ($24.2B) do not cover its long term liabilities ($38.2B).
Debt to Equity History and Analysis
Debt Level: AZN's net debt to equity ratio (61.9%) is considered high.
Reducing Debt: AZN's debt to equity ratio has reduced from 143.4% to 74% over the past 5 years.
Debt Coverage: AZN's debt is well covered by operating cash flow (37.5%).
Interest Coverage: AZN's interest payments on its debt are well covered by EBIT (15.3x coverage).